View ValuationDIAGNOS 将来の成長Future 基準チェック /06現在、 DIAGNOSの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare Services 収益成長21.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 02Diagnos Inc Successfully Completes Renewal Of US-FDA Medical Device Establishment RegistrationDiagnos Inc. had completed the annual registration for its medical device establishment with the U.S. Food and Drug Administration (FDA). Additionally, DIAGNOS would like to remind the reader that the legacy version of CARA, as a Medical Image Management and Processing System, remains cleared for commercialization in the USA. The future version of CARA, which incorporates many other eye-related disease detection algorithms, is in the process of obtaining applicable regulatory approvals as detailed in the press release dated January 13, 2026.お知らせ • Jan 14Diagnos Inc. Advances Regulatory Strategy for Cara in Key Markets: Updates on Health Canada, Fda, and Sfda ProgressDiagnos Inc. provided an update on the regulatory pathway for its AI platform, CARA. This follows the acceleration plan announced on October 8, 2025. The Corporation continues to execute its strategy to secure approvals in three targeted jurisdictions: Saudi Arabia (SFDA): DIAGNOS has formally submitted CARA for marketing approval to the Saudi Food and Drug Authority (SFDA). Canada (Health Canada): The Corporation is actively engaged with Health Canada to ensure full alignment with applicable medical device regulations. DIAGNOS confirms it is on track to submit its formal application for CARA in the course of this current quarter. United States (FDA): Following strategic meetings with the U.S. Food & Drug Administration (FDA), DIAGNOS has clarified the specific requirements to secure 510(k) clearance, paving the way for commercialization in the US market.お知らせ • Dec 10DIAGNOS Inc. announced that it has received CAD 4.001179 million in fundingOn December 9, 2025, DIAGNOS Inc. closed the transaction. The company announced that it has issued 13,337,262 Units at a price of CAD 0.30 per Unit for aggregate gross proceeds of CAD 4,001,178.60. The transaction is oversubscribed. In connection with the Offering, the Company paid a cash commission of CAD 153,974.40, issued 666,863 Units as a corporate finance fee and issued 513,248 broker warrants (the “Broker Warrants”). Each Broker Warrant entitles the holder to acquire a Unit at the Issue Price at any time on or before June 6, 2027. The securities to be issued under the Offering will have a hold period of four months and one day from the Closing Date under applicable Canadian securities laws. Certain related parties of the Company, namely two (2) directors and one (1) officer, participated in the Offering, acquiring an aggregate of 316,665 Units on the same basis as other subscribers. The transaction is oversubscribed.お知らせ • Nov 11DIAGNOS Inc. announced that it expects to receive CAD 2 million in fundingDIAGNOS Inc. announces a brokered private placement to issue 6,666,667 units at a price of CAD 0.30 per unit for gross proceeds of CAD 2,000,000.1 on November 10, 2025. Each Unit shall consist of one common share in the capital of the Company and one common share purchase warrant. Each Warrant shall be exercisable into one additional common share of the Company at a price of CAD 0.40 per Warrant Share at any time for a period of 18 months following the Closing Date. The Offering is expected to close on or around December 3, 2025, or such other dates as agreed upon between the Company and the Lead Agent and is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the Offering will have a hold period of four months and one day from the Closing Date under applicable Canadian securities laws.お知らせ • Nov 01Diagnos Inc. Announces the Appointment of Dr. Philipgpe Couillard as Chairman of the Board of DirectorsDiagnos Inc. announced the appointment of Dr. Philipgpe Couillard as Chairman of the board of directors (the “Board”).Dr. Couillard is a seasoned business advisor and neurosurgeon. He has served in two significant public roles in the government of the province of Quebec (Canada); as Minister of Health and Social Services between 2003 and 2008 and as Premier of the province from 2014 to 2018. Dr. Couillard joined the Board of DIAGNOS on April 1, 2024.お知らせ • Oct 28DIAGNOS Inc. Announces Dr. Pierre-Luc Charlebois Joins Advisory BoardDIAGNOS Inc. announced that Dr. Pierre-Luc Charlebois has joined the Corporation’s Advisory Board. Along with fellow members, Dr. Tomas J. Philipson, former vice chairman of the White House Council of Economic Advisers, Mr. Ed Weiner, a seasoned entrepreneur, and Dr. Barry A. Ginsberg, optometrist, Dr. Charlebois will act as special counsel to the Corporation’s management. Dr. Charlebois is an orthopedic surgeon practicing in the province of Quebec, Canada. Dr. Charlebois earned his orthopedic surgeon medical degree from the University of Montreal. He also holds a master`s degree in Health Economics, Policy and Management from the London School of Economics and Political Science.お知らせ • Sep 06DIAGNOS Inc. announced that it has received CAD 0.1 million in fundingOn September 5, 2025, DIAGNOS Inc. closed the transaction. The company issued 10 units at a price of CAD 10,000 per unit for gross proceeds of CAD 100,000. Each unit consists of one CAD 10,000 unsecured convertible debenture and 10,000 stock warrants. The units have been subscribed by one director of the corporation. Each debenture has a term of 12 months and bears interest at the annual rate of 10%, payable in cash. At the option of the holder of the debenture, the principal amount may be converted, at any time during the term, into common shares of the corporation at a price of CAD 0.28 per share. Each warrant entitles the holder to purchase one share at a price of CAD 0.40 per share, at any time during the term. All securities to be issued as part of the private placement are subject to a statutory hold period ending on January 6, 2026. The private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation.お知らせ • Sep 04DIAGNOS Inc. announced that it expects to receive CAD 0.1 million in fundingDIAGNOS Inc. announces a non-brokered private placement to issue 10 units at a price of CAD 10,000 per unit for gross proceeds of CAD 100,000 on September 3, 2025. Each unit consists of One CAD 10,000 unsecured convertible debenture and 10,000 stock warrants. Each Debenture has a term of 12 months and bears interest at the annual rate of 10%, payable in cash. At the option of the holder of the Debenture, the principal amount may be converted, at any time during the Term, into common shares of the Corporation at a price of CAD 0.28 per Share. One director of the Corporation has committed to subscribe for all of the Units of the Private placement. All securities to be issued as part of the Private placement will be subject to a 4-month statutory hold period. The Private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation.お知らせ • Jul 28DIAGNOS Inc., Annual General Meeting, Sep 25, 2025DIAGNOS Inc., Annual General Meeting, Sep 25, 2025. Location: quebec, brossard Canadaお知らせ • Jun 26DIAGNOS Inc. Announces Dr. Barry A. Ginsberg Joins Advisory BoardDiagnos Inc. announced that Dr. Barry A. Ginsberg, O.D. has joined the Corporation's Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers and Mr. Ed Weiner, a seasoned entrepreneur, to provide valuable insights to DIAGNOS about the US optical market. Dr. Ginsberg brings more than three decades of practice across corporate, retail and private-practice settings, giving him a ground-level view of how new technologies gain traction in high-volume optometry environments. He has repeatedly identified and launched innovative products and services that increased revenue per visit and improved patient retention for leading optical chains. This commercial experience, combined with his expertise in advanced contact-lens fitting and ocular-disease management, will help DIAGNOS refine its go-to-market strategy and demonstrate the tangible ROI of AI-driven screening to investors and practitioners alike. Dr. Ginsberg earned a B.A. in Chemistry with a minor in Economics from Yeshiva University, followed by a B.S. and Doctor of Optometry from the Pennsylvania College of Optometry. His training included an externship at the Feinbloom Low Vision Center in Philadelphia, where he focused on age-related macular degeneration, and another at the Goldschleger Eye Institute in Tel Hashomer Hospital, Israel, where he concentrated on glaucoma and other ocular diseases.お知らせ • Jun 11Diagnos Appoints Ed Weiner, to Its Advisory Board for the United StatesDiagnos Inc. announced that Mr. Ed Weiner has joined the Corporation’s Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers, to provide valuable insights to DIAGNOS about the US optical market. Mr. Weiner is a seasoned entrepreneur and has been a leader in the optical industry for decades. He was the first to introduce Ralph Lauren Eyewear. He also partnered with Walmart to open 400 optical locations within Walmart’s chain of stores. Mr. Weiner was also chairman and founder of National Vision Associates, one of the largest optical retailers in the USA.お知らせ • Jun 05Diagnos Inc. Announces That Tomas J. Philipson Joins the Corporation's Advisory BoardDiagnos Inc. announced that Dr. Tomas J. Philipson has joined the Corporation’s Advisory Board. Dr. Tomas J. Philipson is considered an expert in US economic policy, particularly health care policy and appears often on major media outlets, including Forbes, The Economist, The Wall Street Journal, The New York Times, CNN, BBC, CBS, ABC, CNBC, Fox News, Fox Business, Newsmax, Yahoo Finance, American Voice, Bloomberg, and CSPAN. He currently serves as Managing Partner of the VC firm MEDA Ventures, serves on several corporate boards, and has co-founded several companies, including Precision Health Economics LLC, with an exit in 2015 (currently owned by Blackstone). His government service includes a full-time position as vice chairman and acting chairman of the White House Council of Economic Advisers 2017-20. He previously served as a senior economic adviser to the head of the Food and Drug Administration (FDA) and a senior economic advisor to the head of the Centers for Medicare and Medicaid Services (CMS). Dr. Philipson was appointed to the Key Indicator Commission by the Speaker of the House of Representatives in 2012. He was a scientific advisor to the House of Representatives initiative 21st Century Cures in 2015 and The Biden Cancer Initiative in 2017. He served as a healthcare advisor to Senator John McCain's 2008 presidential campaign. He received numerous worldwide research awards while he was a chaired professor at the University of Chicago. He is a two-time winner of the Arrow Award of The International Health Economics Association, the highest honor in health economics. Other awards include the Garfield Award for Economic Research, the Prêmio Haralambos Simeonidis from the Brazilian Economic Association, and the Milken Institute’s Distinguished Economic Research Award. He received a B.A. in mathematics from Uppsala University in Sweden, an MA in Mathematics from Claremont Graduate School, and an MA and Ph.D. in Economics from the Wharton School and the University of Pennsylvania.お知らせ • Apr 09Diagnos Inc. Provides Update on its Health Canada Medical Device License ApplicationDIAGNOS Inc. provided an update on the progress of its Medical device license application for CARA System, submitted to Health Canada in early September 2024. Following the submission of its application in early September, DIAGNOS has engaged in ongoing communication with Health Canada, providing timely responses to all regulatory requests. After more than 11 proactive inquiries regarding the application's status, the company announced that Health Canada has confirmed that the application is now under "active processing", having progressed from a previous backlog.お知らせ • Feb 26DIAGNOS Inc. to File for FDA Pre-Market Authorization of Its AI-Powered Cara SystemDiagnos Inc. announced that it is officially filing for U.S. Food and Drug Administration (FDA) pre-market authorization of its CARA SYSTEM, a machine-learning-enabled medical device (MLMD). To ensure a smooth regulatory process, DIAGNOS has engaged ORA, a leading clinical research organization specializing in regulatory affairs and clinical development for ophthalmic products. The CARA SYSTEM is designed to assist optometrists and frontline healthcare professionals in analyzing fundus images for the early detection of diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy. By leveraging Artificial Intelligence, DIAGNOS aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.お知らせ • Feb 06DIAGNOS Inc. announced that it has received CAD 2.014611 million in fundingDIAGNOS Inc. announced a non-brokered private placement to issue 6,715,370 units at a price of CAD 0.30 per unit for gross proceeds of CAD 2,014,611 on February 5, 2025. Each Unit consists of one common share and one common share warrant. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending August 5, 2026. In connection with the closing of the Private Placement, the Corporation paid cash commissions totaling CAD 39,246.72 and issued an aggregate number of 130,821 finder’s warrants to five qualified firms acting at arm’s length to the Corporation. Each finder’s warrant entitles the holder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending August 5, 2026. All securities issued as part of the Private Placement are subject to a statutory hold period ending June 6, 2025. The closing of the Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.お知らせ • Oct 26DIAGNOS Inc. announced that it has received CAD 1.5686 million in fundingDIAGNOS Inc. announces the closing of a non-brokered private placement of 5,228,668 units at a price of CAD 0.3 per unit for gross proceeds of CAD 1,568,600.40 on October 25, 2024. Each Unit consists of one common share and one common share warrant. As part of the closing of the Private Placement, 5,228,668 Warrants have been issued to the subscribers. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending April 25, 2026. In connection with the closing of the Private Placement, the Corporation (i) paid cash commissions amounting to CAD 18,207 and (ii) issued an aggregate number of 60,690 finder’s warrants to three qualified firms acting at arm’s length to the Corporation. Each finder’s warrant entitles the holder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending April 25, 2026. All securities issued as part of the Private Placement are subject to a statutory hold period ending February 26, 2025. The closing of the Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.お知らせ • Jul 30DIAGNOS Inc., Annual General Meeting, Sep 25, 2024DIAGNOS Inc., Annual General Meeting, Sep 25, 2024. Location: quebec, brossard Canadaお知らせ • Jun 06DIAGNOS Inc. announced that it has received CAD 1.295821 million in fundingOn June 5. 2024, DIAGNOS Inc. closed the transaction. The company issued 3,502,931 units at an issue price of CAD 0.28 per Unit, for gross proceeds of CAD 980,820.68 in second and final tranche. Each unit will consist of one common share and one share purchase warrant. As part of the closing of the second and final tranche of the Private Placement, 3,502,931 Warrants have been issued to the subscribers. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending December 5, 2025. Combined with the first closing announced on May 9, 2024, the aggregate number of Warrants issued as part of the Private Placement is 4,627,931. In connection with the closing of the second and final tranche of the Private Placement, the Corporation (i) paid cash commissions amounting to CAD 27,804.01 to three qualified firms acting at arm’s length and (ii) issued an aggregate number of 86,800 finder’s warrants to two qualified firms acting at arm’s length. Each finder’s warrant entitles the holder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending December 5, 2025. All securities issued as part of the second and final tranche of the Private Placement are subject to a statutory hold period ending October 6, 2024. The closing of the Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation. The aggregate number of Units is 4,627,931 and the aggregate gross proceeds amount to CAD 1,295,820.68.お知らせ • May 11DIAGNOS Inc. announced that it expects to receive CAD 1.5 million in fundingDIAGNOS Inc. announced a non-brokered private placement of 5,357,142 units at a price of CAD 0.28 per unit for the gross proceeds of CAD 1,500,000 on May 9, 2024. Each unit will consist of one common share and one share purchase warrant. Each warrant can be exercised to purchase one Share at a price of CAD 0.40 per share for a period of 18 months ending November 9, 2025. All securities issued as part of the first tranche of the Private Placement are subject to a statutory hold period ending September 10, 2024. The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation. The corporation expects to close a second and final tranche of the private placement before May 31, 2024. On the same day, the company issued 1,125,000 units at a price of CAD 0.28 per unit for the gross proceeds of CAD 315,000 in its first tranche closing.お知らせ • May 08Diagnos Inc. Announces to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024Diagnos Inc. in collaboration with ETS, École de Technologie Supérieure, is proud to announce its participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting. DIAGNOS will showcase its latest advancements in artificial intelligence applied to retinal imaging, aiming to revolutionize the way retinal anomalies are detected and diagnosed. During ARVO 2024, DIAGNOS will present three groundbreaking topics: AI-Assisted Automated Screening of Retinal Anomalies in OCT Images: A Deep Learning Approach. All that Glitters is not Gold: Are Current Retina Foundation Models Able to Efficiently Detect Hypertensive Retinopathy. Domain Generalization for Diabetic Retinopathy Grading through Vision-Language Foundation Models. OCT Model: DIAGNOS Convolutional Neural Network (CNN) models, based on OCT images, have achieved remarkable accuracy in identifying subtle changes in retinal morphology indicative of various diseases, such as macular edema, diabetic retinopathy, and age-related macular degeneration. These models, trained on large-scale datasets, extract relevant features from images automatically, enabling early detection of retinal anomalies. Early intervention facilitated by these models has the potential to prevent or delay vision loss and associated complications. Hypertensive Retinopathy: The early detection of Hypertensive Retinopathy (HR) is crucial to prevent irreversible damage to the retinal microcirculation as well as risk prediction tools in cardiovascular disease prevention. DIAGNOS is utilizing Foundation Models, pre-trained on diverse datasets and tasks, to achieve high accuracy in identifying early cases of HR. These computer-aided systems offer a cost-effective solution for disease screening using fundus images, providing objective assessments and assisting clinicians in timely intervention. Vision Language Foundation Model: DIAGNOS is exploring a foundation model for color fundus images able to encode images and text information through vision language encoders, driven by expert knowledge supervision via prompt descriptions. This interdisciplinary approach at the intersection of computer vision, natural language processing and medical imaging, aimed at improving the diagnosis and management of diabetic retinopathy through advanced machine learning techniques. DIAGNOS is at the forefront of innovation in the AI world applied to medical systems. These innovative AI systems provide objective assessments and assist clinicians in interpreting complex Retinal Fundus and OCT images. By enhancing diagnostic confidence and reducing variability in interpretation among practitioners, DIAGNOS is pioneering a new era in retinal healthcare.お知らせ • Apr 17DIAGNOS Inc. to Expedite Application for Medical Device License to Health Canada and US FDA Related to its 4 New Analysis Modules, and is Planning ISO 27001 CertificationDIAGNOS Inc. announced that it is working on getting new Health Canada and FDA approval on 4 additional AI analysis modules for commercialisation during third quarter 2024. These additions to DIAGNOS’ service will provide its customers with a flexible AI-assisted image processing and analysis solution for the detection of a wide range of retinopathies in a general population. Specifically, the new modules aim to assist health care professionals in identifying generally abnormal Optical Coherence Tomography retinal images, and in the grading of Fundus images as it relates to signs of AMD (Age-Related Macular Degeneration), DR (Diabetic Retinopathy), or HR (Hypertensive retinopathy). These new AI analytic modules will provide DIAGNOS with the opportunity to grow its revenue faster. The modernisation of its Health Canada license was required by both current clients, the Quebec government as well as being a pre-requisite by Essilor Luxottica in order to distribute its services in Canada, as well as for a future US market. DIAGNOS is also working towards its ISO 27001 Cyber Security application, a certification that is requested from its customers and prospects.お知らせ • Apr 02DIAGNOS Inc. Appoints Philippe Couillard to Its Board of DirectorsDiagnos Inc. announced the appointment of Dr. Philippe Couillard to the Corporation’s board of directors (the “Board”). Seasoned business advisor, neurosurgeon and former university professor, Dr. Couillard served as Premier of the province of Quebec from 2014 to 2018. Between 2003 and 2008, he was the province of Quebec'sMinister of Health and Social Services. Today, Dr. Couillard acts as strategic advisor to Canadian and international organizations. Dr. Couillard’s directorship became effective April 1, 2024.お知らせ • Mar 23DIAGNOS Inc. announced that it has received CAD 0.578 million in fundingOn March 22, 2024, DIAGNOS Inc closed the transaction. The company issued 650,000 units at an issue price of CAD 0.28 per Unit for gross proceeds of CAD 182,000 under second and final tranche. Each Unit consists of One common share and One common share warrant. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending September 22, 2025. The company has paid finder's fees of CAD 7,840 and issued aggregate number of 28,000 finder’s warrants to two qualified firms acting at arm’s length (each a “Finder”). Each finder’s warrant entitles the Finder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending September 22, 2025. All securities issued as part of the second and final tranche of the Private Placement are subject to a statutory hold period ending July 23, 2024.お知らせ • Mar 02DIAGNOS Inc. Appoints Michael Braeuel to Board of DirectorsDiagnos Inc. announce the appointment of Mr. Michael Braeuel to the Corporation's board of directors. Mr. Braeuel has a successful track record as an accomplished entrepreneur with over 30 years of hands-on business experience. Over the years, he has been able to establish, expand, and ultimately sell two highly profitable businesses. One of them is providing engineering and systems integration services for machine vision inspection technology. Michael holds a master degree in engineering. Mr. Braeuel's directorship is effective February 29, 2024.お知らせ • Jan 17Diagnos Inc. Appoints Yves-Stéphane Couture as Chief Operating OfficerDiagnos Inc. announced the appointment of Mr. Yves-Stéphane Couture as Chief Operating Officer. As part of his duties, Mr. Couture will be responsible for the continuous development of product CARA as well as its commercialization worldwide. Mr. Couture joined DIAGNOS in 2017. Since then, he has been a key asset in the development of AI-based solutions used by optometrists and ophthalmologists to detect and classify multiple illnesses through the analysis of fundus pictures as well as retina scans. Yves-Stéphane strongly believes that AI-based solutions is key to solving some of the most important challenges facing healthcare providers in the delivery of care to patients. Mr. Couture’s new role is effective January 15, 2024. Prior to joining DIAGNOS, Mr. Couture led sales and implementation teams with large IT and telecommunication companies, such as Alcatel-Lucent and Teleglobe, where he was in charge of commercializing and implementing complex infrastructure solutions for health care providers and hospitals. Mr. Couture holds a Bachelor degree in administration from the University of Sherbrooke where he also received a master degree in marketing.お知らせ • Dec 05DIAGNOS Inc. announced that it has received CAD 0.640051 million in fundingDIAGNOS Inc. announced a non brokered private placement to issue 1,828,717 units at an issue price of CAD 0.35 per Unit, for gross proceeds of CAD 640,050.95 on December 4, 2023. Each Unit consists of One common share and One-half common share warrant. Each whole warrant can be exercised to purchase one Share at a price of CAD 0.45 per Share for a period of 18 months ending June 4, 2025. An aggregate number of 914,356 Warrants have been issued as part of the Private Placement. In connection with the closing of the Private Placement, the Corporation has committed to pay a cash commission of CAD 11,250 to one qualified firm acting at arm’s length, Optimista Consulting Services Inc. All securities issued as part of the Private Placement are subject to a statutory hold period ending April 5, 2024. The Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.お知らせ • Aug 01DIAGNOS Inc., Annual General Meeting, Sep 28, 2023DIAGNOS Inc., Annual General Meeting, Sep 28, 2023.お知らせ • May 19DIAGNOS Inc. announced that it has received CAD 0.865 million in fundingDIAGNOS Inc. announced a non-brokered private placement of 10% unsecured convertible debentures and stock warrants for gross proceeds of CAD 865,000 on May 18, 2023. The Debentures have a term of 24 months ending May 18, 2025 and bear interest at the annual rate of 10%. At the option of the Debenture holder, the principal amount of the Debenture may be converted, at any time during the Term, into common shares of the Corporation at a price of CAD 0.37 per Share. Any accrued interest on the principal, at time of conversion, will be immediately payable in cash. An aggregate number of 865,000 Warrants have been issued as part of the Private Placement. Each Warrant entitles the holder to purchase one Share at a price of CAD 0.45 per Share, for a period of 18 months ending November 18, 2024. In connection with the closing of the transaction, the Corporation will pay a cash commission of CAD 15,500 to one qualified firm acting at arm’s length, Optimista Consulting Services Inc. All securities issued as part of the transaction are subject to a statutory hold period ending September 19, 2023. The transaction remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.お知らせ • Feb 15DIAGNOS and ETS to Present Research on Mass Screening for Macular Edema at ARVO 2023DIAGNOS and École de Technologie Supérieure (ÉTS) announced that they will be presenting the results of their ground-breaking research on mass screening for macular edema using Optical Coherence Tomography (OCT) at ARVO 2023, the Annual Conference of the Association for Research in Vision and Ophthalmology (ARVO). The research, which has been selected by the ARVO imaging program committee, represents a major advancement in the field of medical imaging and highlights the important work being carried out by DIAGNOS and ÉTS.お知らせ • Feb 01Diagnos Inc Gets the Green Light for the Use of Its Diabetic Retinopathy Screening Technology in Quebec HospitalsDiagnos Inc. announced that the Quebec government has given the green light to Diagnos' Artificial Intelligence (AI) technology to screen and assess Diabetic Retinopathy of patients served by the endocrinology departments of hospitals across the province. This positive milestone comes as the result of a collaboration project initiated in 2018, where Diagnos’ technology was utilized to screen and classify the level severity of the Diabetic Retinopathy disease in patients of the endocrinology department from a major Quebec Hospital. The pilot phase of the project has been successfully concluded, resulting in the production of a final report by government officials. This report has been disseminated to all hospitals in the province, highlighting the cost savings and other benefits of implementing DIAGNOS' technology. Specifically, the report found that using DIAGNOS' technology resulted in cost savings of $85 per patient, as well as additional savings from the optimization and reduction of time required from healthcare workers.お知らせ • Jan 14DIAGNOS Inc. announced that it has received CAD 0.25 million in fundingDIAGNOS Inc. announced a non-brokered private placement of 5 units at an issue price of CAD 50,000 per unit for the gross proceeds of CAD 250,000. Each unit consists of one unsecured convertible debenture and 50,000 stock warrants. Each Warrant entitles the holder to purchase one Share at a price of CAD 0.26 per Share, for a period of 18 months ending July 13, 2024. Each Debenture has a term of 36 months ending January 13, 2026 and bears interest at the annual rate of 10%. At the option of the holder of the Debenture, the principal amount of the Debenture may be converted, at any time during the Term, into common shares of the Corporation at a price of CAD 0.22 per Share. Any accrued interest on the principal, at time of conversion, will be immediately payable in cash. 250,000 Warrants have been issued as part of the transaction. . If, at any time following May 14, 2023, the daily volume weighted average trading price of the Shares is or exceeds CAD 0.40 for 15 consecutive trading days, the company shall have the option to accelerate the expiry of the Warrants. If the company chooses to exercise the acceleration right, the new expiry date of the Warrants will be the 30th day following the notice of such exercise. In connection with the closing of the transaction, the company paid a cash commission of CAD 12,500 to one qualified firm acting at arm’s length, Optimista consulting services Inc. All securities issued as part of the Private Placement are subject to a statutory hold period ending May 14, 2023. The transaction is subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation. The company has raised 1,100,000 units so far. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、DIAGNOS は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:DGNO.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-5-4-4N/A9/30/20250-5-4-4N/A6/30/20250-5-4-4N/A3/31/20250-4-4-4N/A12/31/20240-4-3-3N/A9/30/20240-3-2-2N/A6/30/20240-3-2-2N/A3/31/20240-3-2-2N/A12/31/20230-3-2-2N/A9/30/20230-3-2-2N/A6/30/20230-3-2-2N/A3/31/20230-2-2-2N/A12/31/20221-2-2-2N/A9/30/20221-3-2-2N/A6/30/20221-3-2-2N/A3/31/20220-3-2-2N/A12/31/20210-3-2-2N/A9/30/20210-2-2-2N/A6/30/20210-2-2-2N/A3/31/20210-2-1-1N/A12/31/20200-3-2-2N/A9/30/20200-3-2-2N/A6/30/20200-3-2-2N/A3/31/20200-3-3-3N/A12/31/20190-3-2-2N/A9/30/20190-3N/A-2N/A6/30/20190-4N/A-3N/A3/31/20190-4N/A-2N/A12/31/20180-4N/A-3N/A9/30/20181-4N/A-2N/A6/30/20181-3N/A-1N/A3/31/20181-4N/A-2N/A12/31/20172-4N/A-2N/A9/30/20172-3N/A-2N/A6/30/20172-4N/A-2N/A3/31/20172-3N/A-2N/A12/31/20161-2N/A-1N/A9/30/20160-3N/A-2N/A6/30/20161-3N/A-2N/A3/31/20161-3N/A-2N/A12/31/20151-3N/A-2N/A9/30/20151-3N/A-2N/A6/30/20151-3N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: DGNO.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: DGNO.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: DGNO.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: DGNO.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: DGNO.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: DGNO.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 23:57終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DIAGNOS Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Stefan QuennevilleVentum Financial Corp
お知らせ • Apr 02Diagnos Inc Successfully Completes Renewal Of US-FDA Medical Device Establishment RegistrationDiagnos Inc. had completed the annual registration for its medical device establishment with the U.S. Food and Drug Administration (FDA). Additionally, DIAGNOS would like to remind the reader that the legacy version of CARA, as a Medical Image Management and Processing System, remains cleared for commercialization in the USA. The future version of CARA, which incorporates many other eye-related disease detection algorithms, is in the process of obtaining applicable regulatory approvals as detailed in the press release dated January 13, 2026.
お知らせ • Jan 14Diagnos Inc. Advances Regulatory Strategy for Cara in Key Markets: Updates on Health Canada, Fda, and Sfda ProgressDiagnos Inc. provided an update on the regulatory pathway for its AI platform, CARA. This follows the acceleration plan announced on October 8, 2025. The Corporation continues to execute its strategy to secure approvals in three targeted jurisdictions: Saudi Arabia (SFDA): DIAGNOS has formally submitted CARA for marketing approval to the Saudi Food and Drug Authority (SFDA). Canada (Health Canada): The Corporation is actively engaged with Health Canada to ensure full alignment with applicable medical device regulations. DIAGNOS confirms it is on track to submit its formal application for CARA in the course of this current quarter. United States (FDA): Following strategic meetings with the U.S. Food & Drug Administration (FDA), DIAGNOS has clarified the specific requirements to secure 510(k) clearance, paving the way for commercialization in the US market.
お知らせ • Dec 10DIAGNOS Inc. announced that it has received CAD 4.001179 million in fundingOn December 9, 2025, DIAGNOS Inc. closed the transaction. The company announced that it has issued 13,337,262 Units at a price of CAD 0.30 per Unit for aggregate gross proceeds of CAD 4,001,178.60. The transaction is oversubscribed. In connection with the Offering, the Company paid a cash commission of CAD 153,974.40, issued 666,863 Units as a corporate finance fee and issued 513,248 broker warrants (the “Broker Warrants”). Each Broker Warrant entitles the holder to acquire a Unit at the Issue Price at any time on or before June 6, 2027. The securities to be issued under the Offering will have a hold period of four months and one day from the Closing Date under applicable Canadian securities laws. Certain related parties of the Company, namely two (2) directors and one (1) officer, participated in the Offering, acquiring an aggregate of 316,665 Units on the same basis as other subscribers. The transaction is oversubscribed.
お知らせ • Nov 11DIAGNOS Inc. announced that it expects to receive CAD 2 million in fundingDIAGNOS Inc. announces a brokered private placement to issue 6,666,667 units at a price of CAD 0.30 per unit for gross proceeds of CAD 2,000,000.1 on November 10, 2025. Each Unit shall consist of one common share in the capital of the Company and one common share purchase warrant. Each Warrant shall be exercisable into one additional common share of the Company at a price of CAD 0.40 per Warrant Share at any time for a period of 18 months following the Closing Date. The Offering is expected to close on or around December 3, 2025, or such other dates as agreed upon between the Company and the Lead Agent and is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the Offering will have a hold period of four months and one day from the Closing Date under applicable Canadian securities laws.
お知らせ • Nov 01Diagnos Inc. Announces the Appointment of Dr. Philipgpe Couillard as Chairman of the Board of DirectorsDiagnos Inc. announced the appointment of Dr. Philipgpe Couillard as Chairman of the board of directors (the “Board”).Dr. Couillard is a seasoned business advisor and neurosurgeon. He has served in two significant public roles in the government of the province of Quebec (Canada); as Minister of Health and Social Services between 2003 and 2008 and as Premier of the province from 2014 to 2018. Dr. Couillard joined the Board of DIAGNOS on April 1, 2024.
お知らせ • Oct 28DIAGNOS Inc. Announces Dr. Pierre-Luc Charlebois Joins Advisory BoardDIAGNOS Inc. announced that Dr. Pierre-Luc Charlebois has joined the Corporation’s Advisory Board. Along with fellow members, Dr. Tomas J. Philipson, former vice chairman of the White House Council of Economic Advisers, Mr. Ed Weiner, a seasoned entrepreneur, and Dr. Barry A. Ginsberg, optometrist, Dr. Charlebois will act as special counsel to the Corporation’s management. Dr. Charlebois is an orthopedic surgeon practicing in the province of Quebec, Canada. Dr. Charlebois earned his orthopedic surgeon medical degree from the University of Montreal. He also holds a master`s degree in Health Economics, Policy and Management from the London School of Economics and Political Science.
お知らせ • Sep 06DIAGNOS Inc. announced that it has received CAD 0.1 million in fundingOn September 5, 2025, DIAGNOS Inc. closed the transaction. The company issued 10 units at a price of CAD 10,000 per unit for gross proceeds of CAD 100,000. Each unit consists of one CAD 10,000 unsecured convertible debenture and 10,000 stock warrants. The units have been subscribed by one director of the corporation. Each debenture has a term of 12 months and bears interest at the annual rate of 10%, payable in cash. At the option of the holder of the debenture, the principal amount may be converted, at any time during the term, into common shares of the corporation at a price of CAD 0.28 per share. Each warrant entitles the holder to purchase one share at a price of CAD 0.40 per share, at any time during the term. All securities to be issued as part of the private placement are subject to a statutory hold period ending on January 6, 2026. The private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation.
お知らせ • Sep 04DIAGNOS Inc. announced that it expects to receive CAD 0.1 million in fundingDIAGNOS Inc. announces a non-brokered private placement to issue 10 units at a price of CAD 10,000 per unit for gross proceeds of CAD 100,000 on September 3, 2025. Each unit consists of One CAD 10,000 unsecured convertible debenture and 10,000 stock warrants. Each Debenture has a term of 12 months and bears interest at the annual rate of 10%, payable in cash. At the option of the holder of the Debenture, the principal amount may be converted, at any time during the Term, into common shares of the Corporation at a price of CAD 0.28 per Share. One director of the Corporation has committed to subscribe for all of the Units of the Private placement. All securities to be issued as part of the Private placement will be subject to a 4-month statutory hold period. The Private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation.
お知らせ • Jul 28DIAGNOS Inc., Annual General Meeting, Sep 25, 2025DIAGNOS Inc., Annual General Meeting, Sep 25, 2025. Location: quebec, brossard Canada
お知らせ • Jun 26DIAGNOS Inc. Announces Dr. Barry A. Ginsberg Joins Advisory BoardDiagnos Inc. announced that Dr. Barry A. Ginsberg, O.D. has joined the Corporation's Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers and Mr. Ed Weiner, a seasoned entrepreneur, to provide valuable insights to DIAGNOS about the US optical market. Dr. Ginsberg brings more than three decades of practice across corporate, retail and private-practice settings, giving him a ground-level view of how new technologies gain traction in high-volume optometry environments. He has repeatedly identified and launched innovative products and services that increased revenue per visit and improved patient retention for leading optical chains. This commercial experience, combined with his expertise in advanced contact-lens fitting and ocular-disease management, will help DIAGNOS refine its go-to-market strategy and demonstrate the tangible ROI of AI-driven screening to investors and practitioners alike. Dr. Ginsberg earned a B.A. in Chemistry with a minor in Economics from Yeshiva University, followed by a B.S. and Doctor of Optometry from the Pennsylvania College of Optometry. His training included an externship at the Feinbloom Low Vision Center in Philadelphia, where he focused on age-related macular degeneration, and another at the Goldschleger Eye Institute in Tel Hashomer Hospital, Israel, where he concentrated on glaucoma and other ocular diseases.
お知らせ • Jun 11Diagnos Appoints Ed Weiner, to Its Advisory Board for the United StatesDiagnos Inc. announced that Mr. Ed Weiner has joined the Corporation’s Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers, to provide valuable insights to DIAGNOS about the US optical market. Mr. Weiner is a seasoned entrepreneur and has been a leader in the optical industry for decades. He was the first to introduce Ralph Lauren Eyewear. He also partnered with Walmart to open 400 optical locations within Walmart’s chain of stores. Mr. Weiner was also chairman and founder of National Vision Associates, one of the largest optical retailers in the USA.
お知らせ • Jun 05Diagnos Inc. Announces That Tomas J. Philipson Joins the Corporation's Advisory BoardDiagnos Inc. announced that Dr. Tomas J. Philipson has joined the Corporation’s Advisory Board. Dr. Tomas J. Philipson is considered an expert in US economic policy, particularly health care policy and appears often on major media outlets, including Forbes, The Economist, The Wall Street Journal, The New York Times, CNN, BBC, CBS, ABC, CNBC, Fox News, Fox Business, Newsmax, Yahoo Finance, American Voice, Bloomberg, and CSPAN. He currently serves as Managing Partner of the VC firm MEDA Ventures, serves on several corporate boards, and has co-founded several companies, including Precision Health Economics LLC, with an exit in 2015 (currently owned by Blackstone). His government service includes a full-time position as vice chairman and acting chairman of the White House Council of Economic Advisers 2017-20. He previously served as a senior economic adviser to the head of the Food and Drug Administration (FDA) and a senior economic advisor to the head of the Centers for Medicare and Medicaid Services (CMS). Dr. Philipson was appointed to the Key Indicator Commission by the Speaker of the House of Representatives in 2012. He was a scientific advisor to the House of Representatives initiative 21st Century Cures in 2015 and The Biden Cancer Initiative in 2017. He served as a healthcare advisor to Senator John McCain's 2008 presidential campaign. He received numerous worldwide research awards while he was a chaired professor at the University of Chicago. He is a two-time winner of the Arrow Award of The International Health Economics Association, the highest honor in health economics. Other awards include the Garfield Award for Economic Research, the Prêmio Haralambos Simeonidis from the Brazilian Economic Association, and the Milken Institute’s Distinguished Economic Research Award. He received a B.A. in mathematics from Uppsala University in Sweden, an MA in Mathematics from Claremont Graduate School, and an MA and Ph.D. in Economics from the Wharton School and the University of Pennsylvania.
お知らせ • Apr 09Diagnos Inc. Provides Update on its Health Canada Medical Device License ApplicationDIAGNOS Inc. provided an update on the progress of its Medical device license application for CARA System, submitted to Health Canada in early September 2024. Following the submission of its application in early September, DIAGNOS has engaged in ongoing communication with Health Canada, providing timely responses to all regulatory requests. After more than 11 proactive inquiries regarding the application's status, the company announced that Health Canada has confirmed that the application is now under "active processing", having progressed from a previous backlog.
お知らせ • Feb 26DIAGNOS Inc. to File for FDA Pre-Market Authorization of Its AI-Powered Cara SystemDiagnos Inc. announced that it is officially filing for U.S. Food and Drug Administration (FDA) pre-market authorization of its CARA SYSTEM, a machine-learning-enabled medical device (MLMD). To ensure a smooth regulatory process, DIAGNOS has engaged ORA, a leading clinical research organization specializing in regulatory affairs and clinical development for ophthalmic products. The CARA SYSTEM is designed to assist optometrists and frontline healthcare professionals in analyzing fundus images for the early detection of diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy. By leveraging Artificial Intelligence, DIAGNOS aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.
お知らせ • Feb 06DIAGNOS Inc. announced that it has received CAD 2.014611 million in fundingDIAGNOS Inc. announced a non-brokered private placement to issue 6,715,370 units at a price of CAD 0.30 per unit for gross proceeds of CAD 2,014,611 on February 5, 2025. Each Unit consists of one common share and one common share warrant. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending August 5, 2026. In connection with the closing of the Private Placement, the Corporation paid cash commissions totaling CAD 39,246.72 and issued an aggregate number of 130,821 finder’s warrants to five qualified firms acting at arm’s length to the Corporation. Each finder’s warrant entitles the holder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending August 5, 2026. All securities issued as part of the Private Placement are subject to a statutory hold period ending June 6, 2025. The closing of the Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.
お知らせ • Oct 26DIAGNOS Inc. announced that it has received CAD 1.5686 million in fundingDIAGNOS Inc. announces the closing of a non-brokered private placement of 5,228,668 units at a price of CAD 0.3 per unit for gross proceeds of CAD 1,568,600.40 on October 25, 2024. Each Unit consists of one common share and one common share warrant. As part of the closing of the Private Placement, 5,228,668 Warrants have been issued to the subscribers. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending April 25, 2026. In connection with the closing of the Private Placement, the Corporation (i) paid cash commissions amounting to CAD 18,207 and (ii) issued an aggregate number of 60,690 finder’s warrants to three qualified firms acting at arm’s length to the Corporation. Each finder’s warrant entitles the holder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending April 25, 2026. All securities issued as part of the Private Placement are subject to a statutory hold period ending February 26, 2025. The closing of the Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.
お知らせ • Jul 30DIAGNOS Inc., Annual General Meeting, Sep 25, 2024DIAGNOS Inc., Annual General Meeting, Sep 25, 2024. Location: quebec, brossard Canada
お知らせ • Jun 06DIAGNOS Inc. announced that it has received CAD 1.295821 million in fundingOn June 5. 2024, DIAGNOS Inc. closed the transaction. The company issued 3,502,931 units at an issue price of CAD 0.28 per Unit, for gross proceeds of CAD 980,820.68 in second and final tranche. Each unit will consist of one common share and one share purchase warrant. As part of the closing of the second and final tranche of the Private Placement, 3,502,931 Warrants have been issued to the subscribers. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending December 5, 2025. Combined with the first closing announced on May 9, 2024, the aggregate number of Warrants issued as part of the Private Placement is 4,627,931. In connection with the closing of the second and final tranche of the Private Placement, the Corporation (i) paid cash commissions amounting to CAD 27,804.01 to three qualified firms acting at arm’s length and (ii) issued an aggregate number of 86,800 finder’s warrants to two qualified firms acting at arm’s length. Each finder’s warrant entitles the holder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending December 5, 2025. All securities issued as part of the second and final tranche of the Private Placement are subject to a statutory hold period ending October 6, 2024. The closing of the Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation. The aggregate number of Units is 4,627,931 and the aggregate gross proceeds amount to CAD 1,295,820.68.
お知らせ • May 11DIAGNOS Inc. announced that it expects to receive CAD 1.5 million in fundingDIAGNOS Inc. announced a non-brokered private placement of 5,357,142 units at a price of CAD 0.28 per unit for the gross proceeds of CAD 1,500,000 on May 9, 2024. Each unit will consist of one common share and one share purchase warrant. Each warrant can be exercised to purchase one Share at a price of CAD 0.40 per share for a period of 18 months ending November 9, 2025. All securities issued as part of the first tranche of the Private Placement are subject to a statutory hold period ending September 10, 2024. The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation. The corporation expects to close a second and final tranche of the private placement before May 31, 2024. On the same day, the company issued 1,125,000 units at a price of CAD 0.28 per unit for the gross proceeds of CAD 315,000 in its first tranche closing.
お知らせ • May 08Diagnos Inc. Announces to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024Diagnos Inc. in collaboration with ETS, École de Technologie Supérieure, is proud to announce its participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting. DIAGNOS will showcase its latest advancements in artificial intelligence applied to retinal imaging, aiming to revolutionize the way retinal anomalies are detected and diagnosed. During ARVO 2024, DIAGNOS will present three groundbreaking topics: AI-Assisted Automated Screening of Retinal Anomalies in OCT Images: A Deep Learning Approach. All that Glitters is not Gold: Are Current Retina Foundation Models Able to Efficiently Detect Hypertensive Retinopathy. Domain Generalization for Diabetic Retinopathy Grading through Vision-Language Foundation Models. OCT Model: DIAGNOS Convolutional Neural Network (CNN) models, based on OCT images, have achieved remarkable accuracy in identifying subtle changes in retinal morphology indicative of various diseases, such as macular edema, diabetic retinopathy, and age-related macular degeneration. These models, trained on large-scale datasets, extract relevant features from images automatically, enabling early detection of retinal anomalies. Early intervention facilitated by these models has the potential to prevent or delay vision loss and associated complications. Hypertensive Retinopathy: The early detection of Hypertensive Retinopathy (HR) is crucial to prevent irreversible damage to the retinal microcirculation as well as risk prediction tools in cardiovascular disease prevention. DIAGNOS is utilizing Foundation Models, pre-trained on diverse datasets and tasks, to achieve high accuracy in identifying early cases of HR. These computer-aided systems offer a cost-effective solution for disease screening using fundus images, providing objective assessments and assisting clinicians in timely intervention. Vision Language Foundation Model: DIAGNOS is exploring a foundation model for color fundus images able to encode images and text information through vision language encoders, driven by expert knowledge supervision via prompt descriptions. This interdisciplinary approach at the intersection of computer vision, natural language processing and medical imaging, aimed at improving the diagnosis and management of diabetic retinopathy through advanced machine learning techniques. DIAGNOS is at the forefront of innovation in the AI world applied to medical systems. These innovative AI systems provide objective assessments and assist clinicians in interpreting complex Retinal Fundus and OCT images. By enhancing diagnostic confidence and reducing variability in interpretation among practitioners, DIAGNOS is pioneering a new era in retinal healthcare.
お知らせ • Apr 17DIAGNOS Inc. to Expedite Application for Medical Device License to Health Canada and US FDA Related to its 4 New Analysis Modules, and is Planning ISO 27001 CertificationDIAGNOS Inc. announced that it is working on getting new Health Canada and FDA approval on 4 additional AI analysis modules for commercialisation during third quarter 2024. These additions to DIAGNOS’ service will provide its customers with a flexible AI-assisted image processing and analysis solution for the detection of a wide range of retinopathies in a general population. Specifically, the new modules aim to assist health care professionals in identifying generally abnormal Optical Coherence Tomography retinal images, and in the grading of Fundus images as it relates to signs of AMD (Age-Related Macular Degeneration), DR (Diabetic Retinopathy), or HR (Hypertensive retinopathy). These new AI analytic modules will provide DIAGNOS with the opportunity to grow its revenue faster. The modernisation of its Health Canada license was required by both current clients, the Quebec government as well as being a pre-requisite by Essilor Luxottica in order to distribute its services in Canada, as well as for a future US market. DIAGNOS is also working towards its ISO 27001 Cyber Security application, a certification that is requested from its customers and prospects.
お知らせ • Apr 02DIAGNOS Inc. Appoints Philippe Couillard to Its Board of DirectorsDiagnos Inc. announced the appointment of Dr. Philippe Couillard to the Corporation’s board of directors (the “Board”). Seasoned business advisor, neurosurgeon and former university professor, Dr. Couillard served as Premier of the province of Quebec from 2014 to 2018. Between 2003 and 2008, he was the province of Quebec'sMinister of Health and Social Services. Today, Dr. Couillard acts as strategic advisor to Canadian and international organizations. Dr. Couillard’s directorship became effective April 1, 2024.
お知らせ • Mar 23DIAGNOS Inc. announced that it has received CAD 0.578 million in fundingOn March 22, 2024, DIAGNOS Inc closed the transaction. The company issued 650,000 units at an issue price of CAD 0.28 per Unit for gross proceeds of CAD 182,000 under second and final tranche. Each Unit consists of One common share and One common share warrant. Each Warrant can be exercised to purchase one Share at a price of CAD 0.40 per Share for a period of 18 months ending September 22, 2025. The company has paid finder's fees of CAD 7,840 and issued aggregate number of 28,000 finder’s warrants to two qualified firms acting at arm’s length (each a “Finder”). Each finder’s warrant entitles the Finder to purchase one Share at an exercise price of CAD 0.40 per Share for a period of 18 months ending September 22, 2025. All securities issued as part of the second and final tranche of the Private Placement are subject to a statutory hold period ending July 23, 2024.
お知らせ • Mar 02DIAGNOS Inc. Appoints Michael Braeuel to Board of DirectorsDiagnos Inc. announce the appointment of Mr. Michael Braeuel to the Corporation's board of directors. Mr. Braeuel has a successful track record as an accomplished entrepreneur with over 30 years of hands-on business experience. Over the years, he has been able to establish, expand, and ultimately sell two highly profitable businesses. One of them is providing engineering and systems integration services for machine vision inspection technology. Michael holds a master degree in engineering. Mr. Braeuel's directorship is effective February 29, 2024.
お知らせ • Jan 17Diagnos Inc. Appoints Yves-Stéphane Couture as Chief Operating OfficerDiagnos Inc. announced the appointment of Mr. Yves-Stéphane Couture as Chief Operating Officer. As part of his duties, Mr. Couture will be responsible for the continuous development of product CARA as well as its commercialization worldwide. Mr. Couture joined DIAGNOS in 2017. Since then, he has been a key asset in the development of AI-based solutions used by optometrists and ophthalmologists to detect and classify multiple illnesses through the analysis of fundus pictures as well as retina scans. Yves-Stéphane strongly believes that AI-based solutions is key to solving some of the most important challenges facing healthcare providers in the delivery of care to patients. Mr. Couture’s new role is effective January 15, 2024. Prior to joining DIAGNOS, Mr. Couture led sales and implementation teams with large IT and telecommunication companies, such as Alcatel-Lucent and Teleglobe, where he was in charge of commercializing and implementing complex infrastructure solutions for health care providers and hospitals. Mr. Couture holds a Bachelor degree in administration from the University of Sherbrooke where he also received a master degree in marketing.
お知らせ • Dec 05DIAGNOS Inc. announced that it has received CAD 0.640051 million in fundingDIAGNOS Inc. announced a non brokered private placement to issue 1,828,717 units at an issue price of CAD 0.35 per Unit, for gross proceeds of CAD 640,050.95 on December 4, 2023. Each Unit consists of One common share and One-half common share warrant. Each whole warrant can be exercised to purchase one Share at a price of CAD 0.45 per Share for a period of 18 months ending June 4, 2025. An aggregate number of 914,356 Warrants have been issued as part of the Private Placement. In connection with the closing of the Private Placement, the Corporation has committed to pay a cash commission of CAD 11,250 to one qualified firm acting at arm’s length, Optimista Consulting Services Inc. All securities issued as part of the Private Placement are subject to a statutory hold period ending April 5, 2024. The Private Placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.
お知らせ • Aug 01DIAGNOS Inc., Annual General Meeting, Sep 28, 2023DIAGNOS Inc., Annual General Meeting, Sep 28, 2023.
お知らせ • May 19DIAGNOS Inc. announced that it has received CAD 0.865 million in fundingDIAGNOS Inc. announced a non-brokered private placement of 10% unsecured convertible debentures and stock warrants for gross proceeds of CAD 865,000 on May 18, 2023. The Debentures have a term of 24 months ending May 18, 2025 and bear interest at the annual rate of 10%. At the option of the Debenture holder, the principal amount of the Debenture may be converted, at any time during the Term, into common shares of the Corporation at a price of CAD 0.37 per Share. Any accrued interest on the principal, at time of conversion, will be immediately payable in cash. An aggregate number of 865,000 Warrants have been issued as part of the Private Placement. Each Warrant entitles the holder to purchase one Share at a price of CAD 0.45 per Share, for a period of 18 months ending November 18, 2024. In connection with the closing of the transaction, the Corporation will pay a cash commission of CAD 15,500 to one qualified firm acting at arm’s length, Optimista Consulting Services Inc. All securities issued as part of the transaction are subject to a statutory hold period ending September 19, 2023. The transaction remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.
お知らせ • Feb 15DIAGNOS and ETS to Present Research on Mass Screening for Macular Edema at ARVO 2023DIAGNOS and École de Technologie Supérieure (ÉTS) announced that they will be presenting the results of their ground-breaking research on mass screening for macular edema using Optical Coherence Tomography (OCT) at ARVO 2023, the Annual Conference of the Association for Research in Vision and Ophthalmology (ARVO). The research, which has been selected by the ARVO imaging program committee, represents a major advancement in the field of medical imaging and highlights the important work being carried out by DIAGNOS and ÉTS.
お知らせ • Feb 01Diagnos Inc Gets the Green Light for the Use of Its Diabetic Retinopathy Screening Technology in Quebec HospitalsDiagnos Inc. announced that the Quebec government has given the green light to Diagnos' Artificial Intelligence (AI) technology to screen and assess Diabetic Retinopathy of patients served by the endocrinology departments of hospitals across the province. This positive milestone comes as the result of a collaboration project initiated in 2018, where Diagnos’ technology was utilized to screen and classify the level severity of the Diabetic Retinopathy disease in patients of the endocrinology department from a major Quebec Hospital. The pilot phase of the project has been successfully concluded, resulting in the production of a final report by government officials. This report has been disseminated to all hospitals in the province, highlighting the cost savings and other benefits of implementing DIAGNOS' technology. Specifically, the report found that using DIAGNOS' technology resulted in cost savings of $85 per patient, as well as additional savings from the optimization and reduction of time required from healthcare workers.
お知らせ • Jan 14DIAGNOS Inc. announced that it has received CAD 0.25 million in fundingDIAGNOS Inc. announced a non-brokered private placement of 5 units at an issue price of CAD 50,000 per unit for the gross proceeds of CAD 250,000. Each unit consists of one unsecured convertible debenture and 50,000 stock warrants. Each Warrant entitles the holder to purchase one Share at a price of CAD 0.26 per Share, for a period of 18 months ending July 13, 2024. Each Debenture has a term of 36 months ending January 13, 2026 and bears interest at the annual rate of 10%. At the option of the holder of the Debenture, the principal amount of the Debenture may be converted, at any time during the Term, into common shares of the Corporation at a price of CAD 0.22 per Share. Any accrued interest on the principal, at time of conversion, will be immediately payable in cash. 250,000 Warrants have been issued as part of the transaction. . If, at any time following May 14, 2023, the daily volume weighted average trading price of the Shares is or exceeds CAD 0.40 for 15 consecutive trading days, the company shall have the option to accelerate the expiry of the Warrants. If the company chooses to exercise the acceleration right, the new expiry date of the Warrants will be the 30th day following the notice of such exercise. In connection with the closing of the transaction, the company paid a cash commission of CAD 12,500 to one qualified firm acting at arm’s length, Optimista consulting services Inc. All securities issued as part of the Private Placement are subject to a statutory hold period ending May 14, 2023. The transaction is subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation. The company has raised 1,100,000 units so far.